Liver Cancer

The complete response letter for camrelizumab/rivoceranib for patients with advanced HCC did not specify what deficiencies regulators found.

Amezalpat plus atezolizumab and bevacizumab achieved a 6-month increase for OS compared with atezolizumab and bevacizumab alone in patients with HCC.

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.

Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.

Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.

Updated findings from the CARES-310 trial support the resubmitted application for camrelizumab/rivoceranib in unresectable hepatocellular carcinoma.

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.

The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.

Findings from a retrospective study showed that outpatient robotic hepatectomies resulted in no mortalities across 307 procedures.

Investigators of the HEPATORCH trial will present additional data on toripalimab plus bevacizumab in this population at a future academic conference.

The 5-year follow-up results from CheckMate 040 showed consistent responses with nivolumab/ipilimumab in advanced hepatocellular carcinoma.

The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

The safety of nivolumab plus ipilimumab among those with hepatocellular carcinoma in the CheckMate-9DW trial appears to be comparable with prior reports.

Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.

At 1 and 2 years, patients with hepatocellular carcinoma and narrow surgical margins experienced encouraging recurrence-free survival rates following adjuvant radiotherapy in the phase 2 RAISE trial.

Duration of response results with pembrolizumab plus lenvatinib in advanced hepatocellular carcinoma appear to be ‘promising’ in the phase 3 LEAP-002 trial.

Durvalumab plus bevacizumab and TACE may be a new standard of care in unresectable hepatocellular carcinoma eligible for embolization, according to Riccardo Lencioni, MD.

Patients with hepatocellular carcinoma and Child-Pugh-B liver function appear to have worse overall survival following treatment with regorafenib in the REFINE trial.

Treatment-emergent adverse effects following therapy with fostrox plus lenvatinib among those with hepatocellular carcinoma appear to be manageable in a phase 1a/2a study.

Use of the surgical Epione robot will save a significant amount of time when performing surgery for patients with liver tumors and potentially other cancers, says Govindarajan Narayanan, MD.

The safety profile of durvalumab plus TACE and bevacizumab in patients with hepatocellular carcinoma in the phase 3 EMERALD-1 study appears to consistent with previous findings.

Data from the phase 3 RATIONALE-301 trial appear to support tislelizumab as a potential frontline treatment option for patients with unresectable hepatocellular carcinoma.

Adding TPST-1120 to atezolizumab and bevacizumab appears to improve progression-free survival compared with atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma.

Most adverse effects appear to be grade 1 or 2 among patients with hepatocellular carcinoma and other solid tumors associated with the MYC oncogene receiving OTX-2002 in the phase 1/2 MYCHELANGELO I trial.

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.